Lilly Gains Neuro Disease Biotech in $1.36B Deal
Science and Enterprise,
(Colin Behrens, Pixabay) 15 Oct. 2020. Drug maker Eli Lilly and Co. is acquiring Disarm Therapeutics, a biotechnology company…
The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration
Overview of attention for article published in Neuron, March 2017
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (96th percentile)
-
High Attention Score compared to outputs of the same age and source (84th percentile)
Mentioned by
- news
- 9 news outlets
- blogs
- 1 blog
- 14 X users
- patent
- 20 patents
- wikipedia
- 7 Wikipedia pages
- f1000
- 1 research highlight platform
Readers on
- mendeley
- 416 Mendeley